Recent Alerts
Follow your specialty and individual topics to personalize alerts.
pembrolizumab receives expanded FDA approval in combination with trastuzumab plus fluoropyrimidine- and platinum-containing chemotherapy for first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2) positive gastric or esophagogastric junction adenocarcinoma whose tumors express programmed death-ligand 1 (PD-L1) (combined positive score [CPS] ≥ 1) (FDA Press Release 2025 Mar 19)
400 cases of measles, including 41 hospitalizations and 1 death, have been reported in the state of Texas, United States as of March 28, 2025 (Texas Health and Human Services 2025 Mar 28)
View in Measles
guselkumab (Tremfya) receives expanded FDA approval for the treatment of adults with moderate-to-severely active Crohn disease (CD) (FDA Product Information 2025 Mar)
Acute hypertriglyceridemic pancreatitis in adults management algorithm (REVISED)
View in Acute Pancreatitis in Adults
socioeconomic disadvantage associated with decreased receipt of medication and psychotherapy among persons with alcohol use disorder in the United States (Am J Psychiatry 2024 Nov 1)
View in Alcohol Use Disorder
salpingectomy and tubal occlusion for laparoscopic sterilization may have similar postoperative complication rate at 8 weeks (Lancet Reg Health Eur 2024 Oct)
View in Tubal Sterilization
in critically ill adults with early moderate-to-severe acute respiratory distress syndrome having mechanical ventilation, sedation with inhaled sevoflurane may decrease ventilator-free days at 28 days and increases 90-day mortality compared to IV propofol (JAMA 2025 Mar 18 early online)
View in Analgesia, Sedation, and Use of Paralytics in the Intensive Care Unit
iptacopan (Fabhalta) receives expanded FDA approval for the treatment of adults with C3 glomerulopathy (C3G) to reduce proteinuria (FDA Press Release 2025 Mar 20)
addition of 1- to 4-week deadline for return of fecal immunochemical test (FIT) to invitation letter for colorectal cancer screening slightly increases rate of FIT returned correctly completed and usable within 3 months (Lancet 2025 Mar 12 early online)
adjuvant camrelizumab after definitive chemoradiation therapy with gemcitabine and cisplatin may improve event-free survival compared to observation in adults with locoregionally advanced nasopharyngeal carcinoma (JAMA 2025 Mar 13 early online)
View in Nasopharyngeal Cancer
DynaMed Decisions
Try a FREE tool:
Personalized guidance for pharmacologic treatment for people whose symptoms are at baseline. Includes GOLD, CAT, and mMRC scores.
Announcements
Promotional Pricing for Dyna AI
Limited time promotional pricing is now available for institutions interested in subscribing to Dyna AI on DynaMed. Learn more and request a personalized demo here.
2025 Best in KLAS Software and Services
DynaMed has been recognized as the #1 Clinical Decision Support: Point-of-Care Disease Reference in the 2025 Best in KLAS Research Software and Service award for the fourth time in five years. Read the press release to find out more.
DynaMed Content Eligible for DEA Training Requirements
AMA PRA Category 1 Credit™ activity, designated by Baylor College of Medicine, is eligible for 0.5 credits of education in pain management and the prescription of opioids. See eligible course list or browse the Substance Use and Addiction Medicine specialty.
DynaMed Content Eligible for AAHIVM Continuing Education
Select DynaMed Point-of-Care topics are accepted by the American Academy of HIV Medicine for AMA PRA Category 1 Credit™ activity for continuing education. See eligible topics.
Specialties
Browse and follow our evidence-driven and continually updated topics by specialty.
Browse SpecialtiesDrug Resources
Drug monographs for all patient populations from Micromedex®.
Drug Interaction CheckerLearn how two or more drugs interact and keep your patients safe.